oscient
Waltham, MA-based Oscient Pharmaceuticals (NASDAQ:OSCI) filed for Chapter 11 bankruptcy protection after racking up $183.3 million in debt and slashing hundreds of jobs. The drug maker also agreed to sell the rights to its antibiotic drug gemifloxacin mesylate (Factive), to a subsidiary of Cary, NC-based Cornerstone Therapeutics (NASDAQ:CRTX) for more than $5 million, and is seeking a buyer for its top-selling drug, fenofibrate (Antara), which is prescribed for patients with above-normal cholesterol and triglyceride levels. Si stanno operando per salvarla.



LinkBack URL
About LinkBacks
Reply With Quote
